Diuretic Management in Stage 3b Chronic Kidney Disease

Introduction to Diuretic Therapy

The American College of Cardiology recommends switching from hydrochlorothiazide to a loop diuretic, specifically torsemide 10-20 mg once daily, for patients with Stage 3b CKD (eGFR <45 mL/min/1.73 m²) 1, 2
Loop diuretics maintain efficacy even with markedly impaired renal function (GFR <30 mL/min/1.73 m²), whereas thiazides like hydrochlorothiazide lose effectiveness below this threshold 1, 2
Torsemide is specifically recommended over furosemide due to its longer duration of action (12-16 hours vs. 6-8 hours), once-daily dosing that improves adherence, and more predictable bioavailability in CKD patients 1, 2

The Kidney Disease Outcomes Quality Initiative (KDOQI) work group explicitly disagreed with older recommendations that thiazides should be automatically discontinued when eGFR falls below 30 mL/min/1.73 m² 4, 5
Chlorthalidone (not hydrochlorothiazide) may be considered for resistant hypertension in Stage 3b-4 CKD, as one study showed 25 mg chlorthalidone reduced 24-hour ambulatory BP by 10.5 mm Hg in patients with mean eGFR of 26.8 mL/min/1.73 m² 4, 5
Chlorthalidone is superior to hydrochlorothiazide in advanced CKD based on major BP trials, so if continuing a thiazide, switch to chlorthalidone rather than keeping hydrochlorothiazide 4

For volume overload or edema, start torsemide 10-20 mg once daily, and if inadequate response, increase to 40 mg once daily, then up to maximum 200 mg daily 1, 3
Check serum potassium, sodium, and magnesium within 3 days and again at 1 week after initiating loop diuretic therapy, and continue monitoring at least monthly for the first 3 months, then every 3 months thereafter 1, 2
Assess for hypokalemia and hypomagnesemia, as hypomagnesemia can make hypokalemia resistant to correction 1
Monitor for volume depletion, especially in elderly patients who may be more sensitive to diuretic effects 4

Do not use furosemide as first-line if torsemide is available, as torsemide's pharmacokinetic advantages are particularly important in CKD 1, 2
Do not fail to increase loop diuretic doses in advanced CKD—higher doses are required due to reduced tubular secretion and fewer functional nephron sites 1
Avoid potassium-sparing diuretics when GFR <45 mL/min due to significant hyperkalemia risk, unless specifically indicated and closely monitored 5
Ensure dietary sodium restriction to <2.0 g/day (<90 mmol/day), as diuretics cannot overcome excessive sodium intake 2
Do not combine ACE inhibitors with ARBs regardless of diuretic choice, due to increased risks of hyperkalemia and acute kidney injury 4